VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6010 OBTAINS CLINICAL TRIAL APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. (Incorpor ated in H ong Kong with limi ted liabi lity) (Stock co de: 1093) VOLUNTARY ANNOUNCEMENT ANTIBODY-DRUG CONJUGATE SYS6010 OBTAINS CLINICAL TRIAL APPROVAL The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the antibody-drug conjugate SYS6010 (the “Product”) developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. A number of patent applications of the Product have been submitted in China and overseas. SYS6010 is a monoclonal antibody-drug conjugate which can bind to specific receptors on the tumor surface and achieve tumor cell killing by entering the cells through endocytosis and releasing toxins. The indications for this clinical trial approval are advanced solid tumors. The Product has demonstrated good anti-tumor effects on a variety of cancers in the preclinical studies, providing a promising prospect of demonstrating good efficacy in subsequent clinical trials. By order of the Board CSPC Pharmaceutical Group Limited CAI Dongchen Chairman Hong Kong, 20 April 2023 As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

The release as fetched from its publisher. irasia.com ↗